Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The Human Explanted Heart Program: A translational bridge for cardiovascular medicine

Hao Zhang, Anissa Viveiros, Anish Nikhanj, Quynh Nguyen, Kaining Wang, Wei Wang, Darren H. Freed, John C. Mullen, Roderick MacArthur, Daniel H. Kim, Wayne Tymchak, Consolo M. Sergi, Zamaneh Kassiri, Shaohua Wang, Gavin Y. Oudit

**Abstract**

The progression of cardiovascular research is often impeded by the lack of reliable disease models that fully recapitulate the pathogenesis in humans. These limitations apply to both in vitro models such as cell-based cultures and in vivo animal models which invariably are limited to simulate the complexity of cardiovascular disease in humans. Implementing human heart tissue in cardiovascular research complements our research strategy using preclinical models. We established the Human Explanted Heart Program (HELP) which integrates clinical, tissue and molecular phenotyping thereby providing a comprehensive evaluation into human heart disease. Our collection and storage of biospecimens allow them to retain key pathologic findings while providing novel insights into human heart failure. The use of human non-failing control explanted hearts provides a valuable comparison group for the diseased explanted hearts. Using HELP we have been able to create a tissue repository which have been used for genetic, molecular, cellular, and histological studies. This review describes the process of collection and use of explanted human heart specimens encompassing a spectrum of pediatric and adult heart diseases, while highlighting the role of these invaluable specimens in translational research. Furthermore, we highlight the efficient procurement and bio-preservation approaches ensuring analytical quality of heart specimens acquired in the context of heart donation and transplantation.

**Keywords:** Tissue biobank, Human explanted heart, Heart failure, Pediatric heart diseases, Ventricular assist device, Translational research

**Abbreviations:** ACE2, angiotensin converting enzyme 2; Ang II, angiotensin II; AT\(_1\)R, Ang II type 1 receptor; CAD, coronary artery disease; CHD, congenital heart defects; CVD, cardiovascular diseases; DCM, dilated cardiomyopathy; EAT, epicardial adipose tissue; ECM, extracellular matrix; FA, fatty acid; FD, Fabry disease; HELP, Human Explanted Heart Program; HF, heart failure; HfPEF, heart failure with preserved ejection fraction; HOPE, Human Organ Procurement and Exchange program; LA/RA, left/right atria; LV/RV, left/right ventricles; LVAD, left ventricular assist device; MAHI, Mazankowski Alberta Heart Institute; MD, muscular dystrophy; MI, myocardial infarction; MMP, matrix metalloproteinase; NFC, non-failing control hearts; RAS, renin-angiotensin system; RNA-Seq, RNA-sequencing; TIMP, tissue inhibitor of metalloproteinase.

**Corresponding author at:** Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton T6G 2B7, Alberta, Canada.

**E-mail address:** gavin.oudit@ualberta.ca (G.Y. Oudit).

**https://doi.org/10.1016/j.bbadis.2020.165995**

Received 12 June 2020; Received in revised form 12 October 2020; Accepted 15 October 2020

Available online 22 October 2020

0925-4439/© 2020 Elsevier B.V. All rights reserved.
assist device (LVAD) and heart transplantation [12–15]. However, organ supply from optimal donors severely limits transplantation as a therapeutic option, which causes high waitlist mortality [16–20]. Therefore, there is an urgent need for tailored and improved pharmacotherapies for HF.

Human heart biospecimens remain high on the agenda for mechanistic studies and drug discovery and validation when studying multifaceted human CVD [21–24]. A biobank is a bio-depository that encompasses the collection and storage of biologic samples and associated biological and clinical data to be used for research [25–27]. Importantly, biobanking enables bi-directional approaches to discover novel targets for HF prospectively, or retrospectively verify existing hypotheses derived from previous experimental models. In this review, we outline the methodology and classification of our heart biobank, and we also illustrate the utility of our program for current and future applications to better elucidate the mechanism for human heart disease and to drive drug discovery.

2. Human Explanted Heart Program: overview & background

2.1. Tissue biobanking

The Mazankowski Alberta Heart Institute (MAHI) administers an extensive research-integrated human heart transplant program – the Human Explanted Heart Program (HELP). Established in 2010, HELP is a research partnership between basic scientists, clinicians, and clinician-scientists of the MAHI at the University of Alberta. The primary objective of this program was to serve as an integrative and sustainable platform for discovery, innovation, and improved patient care. Fundamental to this approach is the consistent collection of human explanted heart tissues over the past decade, such that our biobank now contains a breadth of heart diseases, which fosters ongoing collaborations [28–37]. Our biobank contains samples obtained from over 450 specimens with diverse phenotypes coupled with comprehensive clinical phenotypes. We have implemented quality control measures involving tissue collection, processing, biopreservation, and biobanking.

As of May 2020, the HELP heart biobank is primarily comprised of specimens representative of four categories: adult (n = 219) and pediatric (n = 58) failing native hearts, non-failing control hearts (NFC; n = 48), and left ventricular apical cores (n = 136; Fig. 1A). Specimen procurement is an ongoing effort, and as such our inventory continues to increase. For the adult cohort, dilated cardiomyopathy (DCM) remained the most common etiology, followed by coronary artery disease (CAD). Likewise, apical cores were collected from patients with similar etiologies at the time when they received left ventricular assist device (LVAD) as a bridge to heart transplant (Fig. 1A). Yet often, DCM in our inventory remains idiopathic or familial; we have collected a decent amount of specimens with identified cause(s) impairing the myocardium. Specifically, it includes exposure to toxins (i.e., illicit drugs, alcohol), anticancer chemotherapies (i.e., adriamycin), certain infectious diseases (i.e., viral myocarditis) and systemic conditions (e.g., transfusion iron-overload, peri-partum CM, diabetic and thyroid diseases). As for the pediatric specimens, congenital heart defects (CHD) constitute 40% of the collection with hypoplastic left heart syndrome (HLHS) and tetralogy of Fallot being the primary diagnoses (Fig. 1A). In addition to the HF specimens, HELP biobank has also compiled an inventory of the non-failing control (NFC) hearts that serve as the “control” group in the context of cardiovascular research. The NFCs consisted of non-diseased hearts from brain-dead donors obtained through the Human Organ Procurement and Exchange (HOPE) program, which were found unsuitable for transplantation due to various reasons but primarily due to blood type (ABO) and/or human leukocyte antigen (HLA) mismatch. Furthermore, the donor allografts were evaluated and stratified as ideal and marginal based on the reason the organ was declined for transplantation including assessment of clinical parameters (see Section 2.2 for more discussion; Figs. 1A; 2A).

2.2. Source of explanted failing and donor hearts

The failing explanted hearts in our collection comprise of the native hearts of transplant recipients. Therefore, our HELP inventory of specimens reflects the diagnoses seen in patients with advanced HF who are eligible for heart transplant (Figs. 1A; 2A) [18,38]. The high prevalence of cardiac diseases, together with improved survival in patients from advancements in medical and device therapies, have ultimately increased the number of patients with advanced HF. This has induced a supply-demand imbalance for cardiac transplantation, with the number of recipients far exceeding the number of available donor hearts (Fig. 2A). In Canada, for example, the annual number of HF patients (both adult and pediatric) on the waiting lists increased by almost threefold from n = 47 adult and n = 6 pediatric in 2006 to n = 122 adult and n = 35 pediatric patients in 2018, according to the latest administrative data available from the longitudinal national database of the Canadian Organ Replacement Register (Fig. 2B) [39–41]. However, the number of heart transplants has climbed relatively slowly for adult patients with an upsurge only in the recent five years, and has even decreased for pediatric patients during the past thirteen years (Fig. 2B–C) [39–41].

To be eligible for heart transplantation, patients must pass rigorous criteria and thorough assessments, including considerations for relative or absolute contraindications (Fig. 2A) [18,42,43]. Following that, there are two types of assessments to guide the pre-transplant referral. The first includes compatibility tests for matching, such as blood types (e.g., ABO, Rh) and histocompatibility (i.e., HLA), whereas the second involves cardiopulmonary stress testing and prognostic assessments of HF survival (Fig. 2A) [18,43]. The other source of failing hearts (n = 9) in the HELP inventory is from patients who required re-transplantation due to transplant vasculopathy [53]. Heart transplantation cannot exist without organ donors. Occasionally, donor hearts are rejected for transplantation resulting in the organs being offered for research, thus our NFC collection via the HOPE program (Figs. 1A; 2A). This is a provincial organ procurement agency that facilitates the donation, allocation and recovery of the organs for transplantation, but also works jointly with HELP to coordinate the procurement of clinically exempted NFC hearts.

Following the procurement of donor organs, we classify the hearts into “ideal” or “marginal”, taking account of cardiac and extracardiac factors that prevented the donor hearts for being transplanted [44–47]. To illustrate, a series of cardiac and clinical screenings (i.e., 12-lead electrocardiogram and echocardiogram) are performed routinely on the potential donors. Ideal donor hearts may be rejected from transplantation for extracardiac reasons (such as failed compatibility tests, mismatched donor-recipient size) and/or logistical limitations (i.e., extended cold ischemia time; Fig. 2A) [44–46,48,49]. For the NFC classified as marginal hearts, cardiac (e.g., mild systolic dysfunction)
BBA - Molecular Basis of Disease 1867 (2021) 165995

A

Adult Hearts

Pediatric Hearts

LVAD Cores

HOPE Hearts

Non-Ischemic

Ischemic

5cm 5cm

RV_A

RV_P

LV_A

basal

LV_P

middle

LA

RA

Apex

Peri-Infarct

Infarct

Non-Infarct

A

Posterior

Anterior

C

Non-Ischemic

Ischemic

Non-Ischemic and Ischemic

Myocardium

RV

Anterior

Posterior

LV

Anterior Basal

Middle

Posterior Basal

Middle

Septum

Apex

Non-Infarct

Infarct

Peri-Infarct

Septum

Apex

Non-Infarct

Infarct

Non-Infarct

Infarct

Septum

Apex

Frozen 2xOCT

Formalin

EM

RA

Free Wall

Free Wall

Appendage

2xOCT

Formalin

EM

RCA

LAD

LCx

Aorta

Coronary Arteries

Large Vessels

Mitral Valve

Aortic Valve

EAT Valves

Frozen OCT

Formalin

Frozen OCT

Formalin

NCC/RCC/LCC

RV

LV
and baseline clinical (namely advanced age and diabetes) conditions are contraindications for heart transplantation (Fig. 2A) [44–46,48,49] in compliance to the nation-wide organ sharing and allocation agreement [18,38].

3. Human explanted heart procurement: technical features and quality control

3.1. Before collection

The HELP program encompasses Albertans and a wide coverage of out-of-province patients, including Saskatchewan, Manitoba, and northeastern British Columbia. Informed consent and/or assent were obtained from the patients (or power of attorney) in situations when patients were unable to consent or for pediatric patients less than seven years old. The HELP conforms to the ethical principles of the Declaration of Helsinki and has been approved by the institutional review committee and Health Research Ethics Board (HREB) at the University of Alberta. As for the non-diseased heart donors, informed consent was acquired from the family via the institutional HOPE protocol. The pre-collection preparation involved extensive labeling of aluminum foil in which dissected biopsies were wrapped and stored in –80°C freezers or liquid N2, followed by aliquoting of different fixative solutions (e.g., formalin, 2% glutaraldehyde) for preserving tissues. This procedure was conducted by two trainees in the Alberta Cardiovascular and Stroke Research Center (ABACUS). The core laboratory within the ABACUS facility is a dedicated resource, which has allowed us to successfully launch this translational research project. The ABACUS facility has sufficient supplies and equipment to enable tissue collection, including a clean working bench with at least two scalpels, scissors, and forceps, as well as one reusable coronary artery probe with a bendable tip (d ~ 2 mm, for tracing the coronary arteries), metal plate, dissection block and surgical towels. Moreover, ABACUS is equipped with a large liquid N2 tank, ice maker machine, 4 °C fridge, and two freezers with the temperature set to either –80 °C or –20 °C. This setup is paramount to the rapid heart dissection and subsequent storage to maintain tissue integrity.

3.2. During collection

Two trainees with medical training background were on call 24/7 with the cardiac surgical team to procure each consecutively explanted heart. Trainees were informed about the transplant as soon as a donor heart became available, and they would be present on site to receive the explanted heart within 10 min of its explantation. Details of the dissection procedure varied slightly depending on the four collection types as indicated in the subsequent sections.

**Failing hearts:** Before excision, the beating hearts were perfused with ice-cold standard cardioplegic solution via the aortic root after cross-clamping of the aorta by the operating surgeons. The hypothermic cardioplegic solution containing high potassium washed out the remaining blood within the coronary circulation and maintained the excised heart at a low metabolic state. Importantly, it prevented further myocardial injury during the temporary ischemic period. Once removed, the hearts were placed in a container with cold saline, surrounded by ice, for immediate transportation to the ABACUS core laboratory, which is directly connected to the cardiac operating theaters. The hearts were then immediately dissected and processed by two trainees within 10 min while maintained cooled on ice, after a prompt heart weight measurement and macroscopic examination (Figs. 3 and 4). One trainee led the systemic dissection while the other processed the collected tissues. The overall integrity of the removed native heart was maintained to obtain a conventional pathological assessment.

Generally, all sections of the heart were harvested, including myocardium, coronary arteries, valves, larger vessels, and adipose tissues as described earlier in Section 2.1 (Figs. 1B; 3). Methodically, the myocardium was dissected into right and left atrium (both anterior and posterior walls) and its appendage, interventricular septum, left and right ventricles (anterior and inferolateral walls) and apex. The coronary arteries were divided into the left coronary arteries, left anterior descending artery and left circumflex artery, and right coronary artery. The valves included both aorticvalvular (i.e., tricuspid and mitral) and semilunar (e.g., aortic and pulmonary) valves. Larger vessels contained ascending aorta, aortic arch and its branches (e.g., brachiocephalic trunk, left common carotid artery and left subclavian artery) and the descending aorta, when available. Lastly, the adipose tissues were procured from the epicardium from the left and right ventricles and around the epicardial coronary arteries. The ventricular free walls were collected based on either the physiological anatomy (apical, mid and basal segments) for the non-ischemic failing hearts and healthy donor hearts, or location relative to the pathological affected area (infarcted, peri-infarcted and non-infarcted regions) for hearts with CAD (Fig. 3A–C).

The tissue size that was obtained varied depending on the heart weight and shape, but the anatomical positions from where the tissues were captured remained consistent among samples. For instance, positions at approximately one-third and two-thirds below the aortic valves are where we captured the basal and middle ventricular free walls, respectively. As for the major coronary arteries, they were dissected with caution from the explanted hearts, and the vessels were dissected longitudinally to expose the endoluminal surface and cross-sectional landscape. Atherosclerotic lesions were identified and scored by inspecting through a dissecting microscope, and arteries would then be divided into 1.0- to 2.0-cm segments macroscopically designated as disease or disease-free segments. All samples were obtained as transmural biopsies and were further divided to be immediately flash-frozen or TFM-embedded frozen in liquid nitrogen. Meanwhile, the remaining full-thickness pieces were fixed in 10% formalin (containing approximate 4% formaldehyde) or 2% glutaraldehyde for long-term storage. As a bridge to transplantation, the LVAD-supported hearts were also collected when patients received heart transplantation. A 1.0-cm rim of fibrotic myocardium around the apical VAD insertion site was removed and discarded. These tissues offered the opportunity to study the effects of mechanical unloading on failing hearts (Fig. 3C). The excised donor hearts were placed in cold saline immediately following explanation and transported in ice-cool containers to the ABACUS core laboratory.

**LVAD apical cores:** As an integral part of the clinical care of HF patients [14,50–52], MAHI contains one of the largest VAD program in
A. Transplant Listing Criteria and Imbalanced Donor-Recipient Matching

B. Pan-Canada Annual Heart Transplants, Adult vs. Pediatrics, 2006 to 2018

C. Annual Total Heart Transplants, Alberta vs. Canada, 2014 to 2018
North America and involves both pediatric and adult patients (Fig. 1A). At the time of implantation of the LV apical inflow cannula, the apex was collected and divided into two halves: one frozen in liquid nitrogen and the other half further divided into two sections as formalin-fixed for pathological assessment and TFM-embedded for histological staining (Fig. 3D).

**Pediatric failing hearts:** A meticulous examination of the heart anatomy was conducted before each collection, as CHD were the leading causes of HF in pediatric cases, and they were characterized by various structural anomalies (Fig. 4). We have also collected some unique pediatric hearts with novel etiologies including Kawasaki disease. The tissues were also procured by two experienced team members within 10 min.

### 3.2.1. Cellular manipulation

Cryopreserved tissue has its limitation by virtue of the heterogeneous nature (as a mixture of diverse cell types) and the inability to perform experiments to examine specific cellular mechanisms or signaling pathways upon genetic or pharmacological manipulation. Alternatively, primary cells, which are derived and separated from tissue, provide an ideal model to assess the effects of drug candidates or chemical compounds in a specific cell type, such as cardiomyocytes, cardiofibroblasts and vascular smooth muscle cells. Further, adenoviral-based techniques can be utilized to inform potential candidates for gene therapy [32,53–58].

Enzymatic tissue digestion is commonly applied to isolate human cardiomyocytes and cardiofibroblasts with satisfactory yield and viability. Excised myocardial tissue was submerged in the cold formulation and enzymatically digested. Subsequently, the supernatant fraction simultaneously contains cardiomyocytes, cardiofibroblasts and vascular smooth muscle cells. Further, adenoviral-based techniques can be utilized to inform potential candidates for gene therapy [32,53–58].

Enzymatic tissue digestion is commonly applied to isolate human cardiomyocytes and cardiofibroblasts with satisfactory yield and viability. Excised myocardial tissue was submerged in the cold formulation and enzymatically digested. Subsequently, the supernatant fraction simultaneously contains cardiomyocytes, cardiofibroblasts and vascular smooth muscle cells. Further, adenoviral-based techniques can be utilized to inform potential candidates for gene therapy [32,53–58].

### 3.3. After collection

A tissue-based diagnosis in human heart failure has been shown to be more accurate than the clinical-based diagnosis. In fact, in both American and Canadian based studies, there is 17% clinical misdiagnosis rate with the omission of the patients with CAD, and there was a 30% misdiagnosis rate for non-ischemic cardiomyopathy [70,71]. Considering this, all obtained explanted hearts underwent a thorough pathological examination by our co-investigator, who is a board-licensed cardiac pathologist on a routine basis. A close correlation with the clinical features of every patient would be available, including a comparison with the clinical diagnosis.

**Clinical database.** Clinical phenotyping is another essential part of our program. The primary investigators (practicing clinicians) have collected a detailed clinical profile of our patients undergoing heart transplant and/or LVAD insertions via chart review. Our extensive database included demographics, comorbidities, medications, risk factors, electrophysiology, and imaging (e.g., echocardiography, cardiac magnetic resonance imaging, diagnostic coronary angiogram). Right heart catheterization data was obtained to evaluate the degree of pulmonary hypertension, pulmonary capillary wedge pressure (LV filling pressure), and the relationship between RV and LV function. The information collected best represents the patient medical condition at the time the heart tissue was acquired. A secured, uniform coding system and strict encryption were employed to maintain confidentiality.

**Quality control for biobanking management.** Quality control ensures transparency, traceability, and reproducibility across multiple heart collections, which is of pivotal importance in translational research to minimize introducing new variables and given the vast heterogeneity between individuals. We reiterated that the quality assurance standards were strictly implemented throughout the whole process, from preparation to experimentation.

Firstly, uniform coding (A = adult, P = pediatric, L = LV apical core, and H = non-diseased controls) and acronym (Ant = anterior side, Post = posterior side, Mid = middle wall, Base = basal wall, App = appendage, etc.) minimized the systematic errors that could result from mislabeling or misidentification. Temperature and cold ischemia time were the other two critical variables that were rigorously controlled. In addition, refrigerant cold packs were usually avoided as the solidification of fundamental cytoplasm at a temperature below the freezing point of water was presumed to damage the living tissue cells [72,73]. By maintaining hypothermic conditions, this procedure curtails analytical artifacts from potential proteolytic degradation and unstable post-translational modifications [74–77], in conjunction with swift transplantation (~1–2 min) and rapid processing (<10 min) after removal (Fig. 5A).

Secondly, we have gained plenty of experience to optimize the bio-preservation methods for subsequent quality-assured histopathological...
A. Cardiomyopathies

- DCM
- HCM
- RCM
- AC

B. Other Heart Diseases

- IHD
- VHD
- Congenital HD
- Transplant Vasculopathy

C. Non-Failing Donor Hearts

- Ideal
- Marginal

D. Apex Collection

- Non-Ischemic
- Ischemic

Before LVAD

After LVAD

Anterior
Posterior

(caption on next page)
imaging (Fig. 5B). For example, OCT blocks were suspended on top of liquid nitrogen, after embedding the tissues in the cassettes with full TFM immersion, resulting in a slower freezing process without promoting crystallization or matrix cracking inside the tissues (Fig. 5B). For another, all the tissues were entirely soaked with different fixative buffers and nicely embedded in color-coded blocks for sectioning and mounting for immunofluorescent and immunohistochemical examinations (Fig. 5B-C); other details are omitted for the consideration of a concise body of work.

Thirdly, standard operating procedures for handling the frozen human heart specimens for RNA and protein extractions were well established. Cross-contamination between samples was avoided by decontaminating the cutting tools with 75% ethanol, followed by 10% bleach. To reduce the unpredictable impacts of warmth, samples were processed frozen with surrounding liquid nitrogen. Aliquots were prepared each time to avoid multiple freezing-thawing cycles, yet the total cycle times were tracked using the archival system that we developed for documenting sample usage, sharing, and retrieving information. Moreover, all frozen samples were safely stored in the cryogenic storage facility consisting of six –85 °C freezers and five liquid nitrogen tanks with a real-time temperature monitoring system (Fig. 5D).

4. Use and application of the explanted heart samples

The HELP program has offered the unique opportunity to study the correlates of tissue mechanisms in the context of the broader clinical phenotype of each patient. Specifically, we were able to acquire biomolecular data from diseased myocardial samples to formulate and test hypotheses informed by our ongoing translational studies (i.e., sexually dimorphic responses post-MI, age-dependent or development-specific pathogenesis underlying DCM). Conversely, findings deciphered from the explanted hearts would be applied to gene-based approaches (e.g., adenovirus vector-mediated methods) and/or genetic models to manipulate specific pathways and to examine its downstream
B. Sample Bio-preservation Methods

1. Tissue Collection

2. Long-term Sample Storage

C. Experimental Applications

A. Tissue Collection

D. Long-term Sample Storage

E. Systems Biology: Transcriptomic Analysis

TTN CDH5 Overlay DAPI
NPPA DCN Overlay DAPI
MYH11 KCNJ8 Overlay DAPI

(caption on next page)
effects. As such, this bi-directional approach to translation research truly bridges a critical link to both basic science and to clinical medicine.

4.1. Systems biology

Multi-omics approaches, including genomics, transcriptomics, proteomics, and metabolomics were integrated into our analysis on the explanted human heart tissues. Compared with conventional techniques, systems biology provides a non-biased approach for the identification of novel tissue biomarkers and pathways implicated in CVD [78–80]. In this context, the multi-omics platform would facilitate the generation of a navigated “roadmap” connecting genotype to phenotype with potential clinical applicability for CVD patients.

**Genomic analyses.** The polygenetic nature of end-stage HF makes an unbiased, genome-wide analysis a useful tool to identify the underlying basis of heart disease [81–84]. Slow progress has been made on understanding the genetic underpinnings of complex CVD due to confounding factors like extrinsic variables and genetic variation in susceptibility to disease [83]. Current technique for genotyping is based on gene panel based testing in which a predefined set of genes are examined in the diseased specimens. However, more advanced testing using whole-genome sequencing (WGS), for example, maps the entire genome, while whole-exome sequencing (WES) focuses on all the exon (protein-coding) regions in a genome. Though there has been a recent explosion in the number of genes responsible for cardiomyopathies, genotype-phenotype correlations are generally lacking, and studies on the underlying biological mechanisms for numerous mutations and gene variants need to be conducted [85].

**Transcriptomic analyses.** The study of transcriptome examines all sets of transcribed RNA molecules from protein-coding messenger RNA (mRNA) to noncoding RNAs such microRNA and long non-coding RNA (lncRNA). The realization of genome-wide profiling of heart diseases necessitates the incorporation of transcriptomic analysis as an integral part, as incomplete interpretation arises without transcription linking genetic information and proteomic expression [80,86]. With regard to techniques, there are two approaches applied most frequently: hybridization-based microarrays and RNA-sequencing (RNA-Seq). Microarrays are tools that detect the expression of thousands of genes using chips that contain pre-determined probes [87], and hybridization happens when the complementary DNA (reversely transcribed from mRNA) binds to the DNA probes yielding a specific fluorescent color and gene expression is represented as the color intensity after normalized to the corresponding controls [88]. As for analysis on a more global scale, RNA-Seq is more readily employed, where high-throughput sequencing methods (i.e., next-generation sequencing technologies) are used to provide insights into the transcriptomes of explanted heart tissue in an unbiased manner including single-cell and single-nucleus analyses [89–91]. In addition, RNA-Seq analysis provides an improved and expanded RNA profiling with higher specificity and sensitivity, especially for less abundant transcripts. RNA expression profiling has provided new insight into disease pathogenesis including transcriptome signatures of DCM hearts with ventricular arrhythmia [36,92–95]; however, full knowledge of the broader repertoire of healthy hearts’ molecular and genetic landscape is fundamental. To achieve that, we profiled both cells and nuclei from six distinct cardiac anatomical regions (apex, septum, left/right atria and ventricles) of the non-failing donor hearts, and constructed a most comprehensive transcriptome atlas as the reference framework to advance mechanistic exploration into heart diseases (Fig. 5E) [36,37,93–96].

**Proteomic analyses.** Proteomics offer the capability to capture protein structures from whole proteome sequencing, identify post-translationally modified peptides and monitor the subcellular protein-protein interactions [97–100]. Among them, post-translational modifications, including phosphorylation, glycosylation, acetylation and ubiquitination add further diversity to the proteome, which may offer a targetable approach to HF management including the identification of novel biomarkers and therapeutic targets [101].

**Metabolomics and correcting metabolic defects.** Dysregulated metabolism contributes to the progression of myocardial dysfunction in obesity, diabetes and HF in part due to changes in mitochondrial dynamics post-MI, or varied epigenomic remodeling (e.g., histone modification, DNA methylation, non-coding RNAs in obese-induced cardiomyopathy) [11,32,102,103]. A switch in energy supply from glucose metabolism to fatty acid β-oxidation occurs in heart disease [11], and accordingly, inhibiting fatty acid β-oxidation and stimulating the use of other fuels such as glucose and ketones is a promising therapeutic approach in HF [11,104]. Pyruvate dehydrogenase kinase isozone 4 and malonyl-CoA decarboxylase inhibitors are being developed as novel therapies [105], which can be readily tested in human HF cardiomyocytes to examine changes in metabolism. Our metabolomics approach showed elevated branch chain amino acids levels in explanted failing human hearts indicating impaired cardiac branch chain amino acid catabolism in human heart failure, while enhancing branch chain amino acids oxidation improved cardiac function in the failing heart [106].

4.2. Reverse remodeling of the failing human heart: impact of LVAD therapy

Extensive studies alleged the beneficial adaptive or reverse remodeling upon LVAD implantation, but several questions remain unanswered such as identification of markers of recovery, genetic basis underlying disparate outcomes among patients, and longitudinal effects of mechanical circulatory support [34,59,61,107–112]. The HELP program offers the ability to investigate them comprehensively on a large scale. We would prioritize the apical tissue taken at the time of LVAD insertion and compare with the LV myocardium procured from the same patient undergoing subsequent transplantation. In addition, genetic or proteomic markers underlying RV failure, a persistent limitation of current LVAD therapy [113], would also be incorporated into our analysis.

4.3. Targeted approaches of the HELP program

4.3.1. Enhancing angiotensin-converting enzyme 2 and apelin pathways as potential novel therapy for human HF

Activation of the systemic RAS and the generation of angiotensin II (Ang II) by angiotensin-converting enzyme (ACE) is major driver of cardiovascular diseases [114–116]. In contrast, ACE2 functions as a peptidase, monokarboxyptidase which generates Ang 1–7 from Ang II [117–119] leading to activation of the widely expressed Mas receptor in the CV system [55,119,120]. ACE2 is the receptor for the SARS-CoV-2 and is associated with myocarditis, microvascular dysfunction, LV dysfunction in COVID-19 patients [116,121,122]. Therapeutic strategies
focus on maintaining the balance between the two arms by either enhancing ACE2 (e.g., administration of recombinant human ACE2, rhACE2) or suppressing Ang II actions (i.e. blockade of AT1R, or ACE inhibition) in the context of HF, whereby we have gained substantial understandings from rodent models combined with human tissue explants [55,116,123–127]. Interestingly, an alternative ACE-independent pathway for converting Ang I to Ang II was found in the heart driven by the serine protease, chymase family [128,129]. In accordance, there is incomplete suppression of plasma Ang II levels in patients who took ACE inhibitors chronically [130–132], and using the HELP platform we demonstrated increased chymase protein levels and activity in explanted DCM hearts which likely contributed to the elevated tissue Ang II despite ACE inhibition [133].

Apelin is an endogenous family of peptides which binds and activates the G protein-coupled receptor, apelin receptor [134]. Similar to the AT1R, the apelin receptor is highly expressed in the cardiovascular system [134] and the apelin axis is proposed to have the opposite effects to the Ang II/AT1R pathway [135]. Apelin mediates a positive inotropic effect and by activating eNOS results in mild vasodilation and afterload reduction [136,137]. Loss of apelin could lead to increased mortality, greater adverse remodeling post-MI, exacerbated myocardial damage in response to myocardial ischemia-reperfusion injury, and higher susceptibility to vascular events such as abdominal aortic aneurysm and peripheral arterial diseases [58,138,139]. Apelin levels are decreased in the coronary arteries from explanted hearts with myocardial infarction [140] but increased in aortic samples obtained from patients with aortic aneurysm [58]. The metalloprotease, nephrilysin, is a major physiological enzyme, apart from ACE2, that degraded apelin peptides and inactivated the apelineric system providing important insight into the therapeutic benefit of sacubitril/valsartan therapy in HF [134,141]. Enhancing the apelin/apelin receptor axis has emerged as the novel pathway for the treatment of cardiovascular diseases, such as obesity-associated cardiac hypertrophy and contractile dysfunction [142].

4.3.2. Correcting the dysregulated extracellular matrix (ECM): role of TIMPs

At the tissue level, cardiomyocytes are surrounded and supported by the ECM, which maintains stability and the architectural integrity of the myocardium. The matrix metalloproteinases (MMPs) are the predominate proteases that regulate the ECM homeostasis by degrading the ECM proteins. This process can be blocked physiologically by the tissue inhibitor of metalloproteinases (TIMPs) [143–147]. Maladaptive myocardial remodeling is characterized by an overall imbalance in ECM turnover, which can result in excess accumulation or disruption of the ECM structural proteins, mainly collagens, leading to impaired systolic performance and diastolic dysfunction in failing hearts [35,148–150]. In addition, insufficient ECM remodeling can lead to LV dilation and rupture, resulting in a high proportion of early sudden death post-MI [151–153]. Myocardial TIMP-1, TIMP-3 and TIMP-4 were reduced in patients having CAD and DCM, [154,155], while TIMP2 markedly increased in later-stage DCM patients [156].

Despite similar phenotypes characterized as systolic dysfunction and eccentric ventricular dilation, pediatric DCM is distinct from adult DCM. Accordingly, there are no proven effective therapies for HF in pediatric patients with DCM [157,158]. We discovered disparate remodeling patterns of the fibrillar and non-fibrillar ECM components, such as glycosaminoglycans and proteoglycan that exists between the pediatric and adult DCM groups [35]. This finding may underline the pathological basis for differential fibrotic reverse remodeling and distinct affinity to the transforming growth factor-β pathway [35], which provides insights as to why pediatric HF patients were less responsive to HF therapies based on clinical trials in adults. The use of explanted failing hearts from children and adults provides an important opportunity to examine the ECM remodeling and its relationship with advanced HF.

5. Future directions of HELP program

5.1. Investigation of inherited cardiomyopathies

Our large and diverse collection of samples gives us the opportunity to investigate the pathophysiology and genetics associated with various cardiomyopathies [159–162]. We have the unique access to LVAD cores and explanted hearts of patients diagnosed with Fabry disease (FD), muscular dystrophy (MD) and other types of genetic cardiomyopathies. FD is an X-linked recessive lysosomal storage disorder, identifiable by the accumulation of glycosphingolipids, leading to multisystem disease [163]. Cardiac complications associated with FD include arrhythmias, LV hypertrophy, and diastolic dysfunction; progression of heart disease in FD results in HFrEF [165,166]. Assessment of human heart tissue through histological staining and genetic sequencing will provide critical insights into the adverse remodeling pathways associated with FD as well as the HFrEF phenotype. MD describes a family of inherited neuromuscular diseases with systemic manifestations [160]. Heart disease, characterized by cardiomyopathy and arrhythmias, is recognized as the primary cause of morbidity and mortality in these patients [165–167]. At the cellular level, Duchenne MD and limb-girdle MD are characterized by the absence or dysfunction of critical cytoskeletal proteins, which leaves cardiomyocytes vulnerable to contractile and shearing forces [165]. Importantly, the correlation of our tissue findings to clinical characteristics could serve to improve patient prognosis through a precision medicine-based approach.

5.2. Epicardial adipose tissue and its relationship with heart disease

Adipose tissue of the heart can be divided into two distinct subsets: the epicardial adipose tissue (EAT) and the pericardial adipose tissue (PAT). The EAT is a visceral fat depot with anatomic proximity to the myocardium, located between the visceral pericardium and myocardium [168–171]. In fact, the close relationship between the myocardium and EAT is exemplified in that they share a common microcirculation. Healthy EAT accounts for approximately 15% of total cardiac mass and primarily resides in the atrioventricular and interventricular grooves (Fig. 3C). However, in diseased states, EAT volume increases and expands to cover the ventricles and the entire epicardial surface [168,171,172] (Fig. 3A–B). Physiologically, the EAT maintains fatty acid (FA) homeostasis to both mobilize FA for oxidation, which in general meets 50–70% of the metabolic demand of the heart, as well as sequester excess FA to circumvent lipotoxicity [172,173]. Further, at physiological volumes, the EAT secretes anti-inflammatory cytokines and adipokines, including adiponectin, leptin, and apelin [174]. However, the pathological progression of CAD and HF is associated with a shift in the EAT secretosome, favoring a proinflammatory cytokine profile and excess release of FA [169,171,174,175]. Importantly, cardiac adipose tissue is limited in laboratory mice, and when present is restricted to the atrioventricular groove [28,176]. Therefore, this highlights the utility of our program to obtain and study EAT from explanted human hearts, offering an optimal platform to study EAT tissue and to unravel its close connection with human heart disease.

5.3. Cardiac electrophysiology and ventricular optical mapping

Ventricular arrhythmias and sudden cardiac death account for 50% of the mortality in patients with advanced HF [177]. Our studies have provided an improved understanding of the mechanism of ventricular fibrillation and the role of signaling pathways and late sodium current [178,179]. The MiCAM Ultima camera system incorporates novel image sensors with high-speed image acquisition while retaining maximal quantum efficiency, and the high signal-to-noise ratio allows for detection of activation times from the first derivative of optical signals during ventricular fibrillation without spatial averaging. We have recently described the genetic and electrophysiological characteristics of a
patient with familial Long QT syndrome caused by missense mutations in KCNH2 [180]. The ability to characterize the electrophysiological changes at a cellular level coupled with the optical mapping of the electrical activation of the whole heart will offer unique insights into the mechanism of ventricular arrhythmias.

6. Conclusions

There are limitations at different stages of the HELP and HOPE programs that need to be acknowledged. Prior to collection, we are limited both by the time of organ procurement and the general heterogeneity of patients. HOPE donors spend an average of 4 days in hospital prior to the declaration of brain death while receiving ongoing therapy. The issue of heterogeneity is intrinsic to working with human samples; comorbidities, lifestyle, and pharmaceutical interventions in HF may affect experimental results. However, access to clinical data allows us to assess specimens and perform subsequent subgrouping. Further, the pathological effects of the adrenergic storm (associated with brain death) on the donor hearts can alter the tissue characteristics in the NFC hearts we have collected. Indeed, some of the data acquired from the control group might not be true representatives of the healthy heart in vivo. Following collection, the challenge of working exclusively with frozen clinical specimens or short-lived primary cardiomyocytes limits the analysis and exploration of dynamic biological mechanisms, which could be unveiled when combined with animal models. Lastly, our patient cohorts were all at end-stage HF and thus we captured a single time point of the entire disease course. Therefore, despite the limitations of our program, our human explanted heart tissue biobank constitutes a unique platform for cardiovascular translational research.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

We would like to acknowledge the professional and multidisciplinary collaborations among all the HELP team members, as well as the support from altruistic donors and their families. Also, we acknowledge the funding from the Canadian Institutes of Health Research (CIHR), Canada Research Chair (CRC) and Heart & Stroke Foundation to GYO. HZ is supported by the China Scholarship Council (CSC) Award.

References

[1] G.A. Roth, et al., Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017, Lancet 392 (10159) (2018) 1736–1788.
[2] E.J. Benjamin, et al., Heart disease and stroke statistics-2019 update: a report from the American Heart Association, Circulation 139 (10) (2019) e55–e528.
[3] B. Ziaieian, G.C. Fonarow, Epidemiology and etiology of heart failure, Nat. Rev. Cardiol. 13 (6) (2016) 368–378.
[4] E. Braunwald,M.R. Bristow, Congestive heart failure: fifty years of progress, J. Am. Heart Assoc. 9 (7) (2020), e01456.
[5] A.G. Masoud, et al., Apelin directs endothelial cell differentiation and vascular remodeling, and transcriptional reprogramming, Am. J. Physiol. Heart Circ. Physiol. 315 (6) (2018) 957–968.
[6] H. Zhang, et al., Role of iron metabolism in heart failure: from iron deficiency to iron overload, Biochim. Biophys. Acta 1865 (7) (2019) 1925–1937.
[7] G.Y. Oudit, et al., L-type Ca 2+ channels provide a major pathway for ion entry into cardiomyocytes in iron-overload cardiomyopathy, Nat. Med. 9 (9) (2003) 1159–1164.
[8] G.D. Lopaschuk, et al., Myocardial fatty acid metabolism in health and disease, Physiol. Rev. 90 (1) (2010) 207–258.
[9] P. Rosignoli, et al., Heart failure drug treatment, Lancet 393 (10175) (2019) 1034–1044.
[10] D.M. Spitler, et al., Cardiac Med1 deletion promotes early lethality, cardiac remodeling, and transcriptional reprogramming, J. Am. Coll. Cardiol. 14 (1) (2019) 53–65.
[11] P. Perel, et al., Comparison of treatment effects between animal experiments and clinical trials: systematic review, BMJ 334 (7586) (2007) 197.
[12] H.B. van der Worp, et al., Can animal models of disease reliably inform human studies? PLoS Med. 7 (3) (2010), e1000245.
[13] M.R. Mehra, et al., The 2016 International Society for Heart Lung Transplantation (ISHLT) consensus statement on heart transplant listing criteria, J Heart Lung Transplant. 39 (4) (2020) 533–554.
[14] X. Chen, et al., Endothelial and cardiomyocyte PI3Kβ divergently regulate cardiac remodeling in response to ischaemic injury, Cardiovasc. Res. 115 (8) (2019) 1343–1356.
[15] D.D. Hall, et al., Ectopic expression of Cdk5 induces eccentric hypertrophy and heart failure, JCI insight 2 (15) (2017), e92476.
[16] J.G. Zaroff, et al., Maximizing use of organs recovered from the cadaver donor: implications for arrhythmogenesis, Biochim. Biophys. Acta 1832 (12) (2013) 309–315.
[17] P. Bartels, A. Kotte, Wildlife biomaterial banking in Africa for now and the future, J. Environ. Monit. 8 (8) (2006) 779–782.
[18] W. Paskal, et al., Aspects of modern biobank activity – comprehensive review, Pathol. Oncol. Res. 24 (4) (2018) 771–785.
[19] V.B. Patel, et al., ACE2 deficiency worsens epicardial adipose tissue inflammation and cardiac dysfunction in response to diet-induced obesity, Diabetes 65 (1) (2016) 85–95.
[20] K.M. Späth, et al., Cardiac Med1 deletion promotes early lethality, cardiac remodeling, and transcriptional reprogramming, Am. J. Physiol. Heart Circ. Physiol. 312 (4) (2017) H1768–H1780.
[21] A.G. Masoud, et al., Apelin directs endothelial cell differentiation and vascular repair following immune-mediated injury, J. Clin. Invest. 130 (1) (2019) 94–107.
[22] S.S. Sakamuri, et al., Differential impact of mechanical unloading on structural and constructural components of the extracellular matrix in advanced human heart failure, Transl. Res. 172 (2016) 30–44.
[23] S. Jana, et al., Disparate remodeling of the extracellular matrix and proteoglycans in failing pediatric versus adult hearts, J. Am. Heart Assoc. 7 (19) (2018), e01427.
[24] N. Parajuli, et al., Determinants of ventricular arrhythmias in human explanted hearts with dilated cardiomyopathy, Eur. J. Clin. Investig. 45 (12) (2015) 1289–1296.
[25] M. Litičinková, et al., Cells of the adult human heart, Nature (2020), https://doi.org/10.1038/s41586-020-2797-9.
[26] G. Haddad, et al., Canadian Cardiovascular Society Consensus Conference update on cardiac transplantation 2008: executive summary, Can. J. Cardiol. 25 (4) (2009) 197–205.
[27] Canadian Organ Replacement Register, Organ Replacement in Canada: CORR Annual Statistics, Available from: https://www.cci.ca/en/organ-replacement-in-canada-corr-annual-statistics-2019, 2019. (Accessed 1 March 2020).
[28] Canadian Organ Replacement Register, e-Statistics on Organ Transplants, Waiting Lists and Donors, Available from: https://www.cci.ca/en/e-statistics-on-organ-transplants-waiting-lists-and-donors, 2019. (Accessed 3 March 2020).
[29] Canadian Society of Transplantation, Transplant Programs & OPOs, Available from: https://www.cst-transplant.ca/cgi/page.cgi/transplant-programs-opos.html , 2020. (Accessed 5 March 2020).
[30] J. Conaway, A.I. Dipchand, Heart transplantation in children, Pediatr. Clin. N. Am. 57 (2) (2010) 353–372.
[31] M.R. Mehra, et al., The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update, J. Heart Lung Transplant. 35 (1) (2016) 1–23.
[32] J.X. Hu, et al., Status on heart transplantation in China, Chin. Med. J. 128 (23) (2015) 3238–3242.
Apelin is a negative regulator of angiotensin II-mediated J.C. Zhong, et al., Targeting the apelin pathway as a novel therapeutic approach K. Wang, M. Gheblawi, G.Y. Oudit, Angiotensin converting enzyme 2: a double-edged sword, Circulation 142 (5) (2020) 426–428. M.A. Crackower, et al., Regulation of myocardial contractility and cell size by distinct PKA-FTEN signaling pathways, Cell 110 (6) (2002) 737–749. G.Y. Oudit, et al., The role of ACE in cardiovascular physiology, Trends Cardiovasc. Med. 13 (3) (2003) 93–101. V.B. Patel, et al., Role of the ACE2/Angiopoietin 1-7 axis of the renin-angiotensin system in heart failure, Circ. Res. 118 (8) (2016) 1313–1326. S. Bodiga, et al., Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47(phox) NADPH oxidase subunit, Cardiovasc. Res. 91 (1) (2011) 151–161. G.Y. Oudit, et al., Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice, Cardiovasc. Res. 75 (1) (2007) 29–36. V.B. Patel, et al., Cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1–7 in experimental heart failure in angiotensin-converting enzyme 2–null mice, Hypertension 59 (6) (2012) 1195–1203. G.Y. Oudit, J.M. Penninger, Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptide for heart failure therapy, Curr. Heart Fail. Rep. 8 (3) (2011) 176–183. V.B. Patel, et al., Antagonism of angiotensin 1–7 prevents the therapeutic effects of recombinant human ACE2, J. Mol. Med. (Berl.) 93 (9) (2015) 1003–1013. H. Urata, et al., Angiotensin II-forming pathways in normal and failing human hearts, Circ. Res. 66 (4) (1990) 883–890. H. Urata, et al., Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the heart, J. Biol. Chem. 265 (36) (1990) 22348–22357. L. Juillerat, et al., Determinants of angiotensin II generation during converting enzyme inhibition, Hypertension 16 (5) (1990) 564–572. R.M. van de Wal, et al., Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition, Int. J. Cardiol. 106 (3) (2006) 367–372. E. Roig, et al., Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure, Eur. Heart J. 21 (1) (2000) 53–57. R. Banu, et al., Roles of angiotensin peptides and recombinant human ACE2 in heart failure, J. Am. Coll. Cardiol. 69 (7) (2017) 805–819. J.C. Zhong, et al., Targeting the apelin pathway as a novel therapeutic approach for cardiovascular diseases, Biochem. Biophys. Acta 1863 (8) (2017) 1942–1950. S.M. Kazemi-Bajestani, et al., Targeting the ACE2 and apelin pathways are novel therapies for heart failure: opportunities and challenges, Cardiol. Res. Pract. 2012 (2012) 823193. S.L. Pitkin, et al., International Union of Basic and Clinical Pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function, Pharmacol. Rev. 62 (3) (2010) 331–342. A.G. Japp, et al., Acute cardiovascular effects of apelin in human: potential role in patients with chronic heart failure, Circulation 121 (16) (2010) 1818–1827. Z.Z. Zhang, et al., Apelin is a negative regulator of angiotensin II-mediated adverse cardiac remodeling and dysfunction, Hypertension 70 (6) (2017) 1165–1175. D. Liang, et al., Therapeutic efficacy of apelin on transplanted mesenchymal stem cells in hindlimb ischemic mice via regulation of autophagy, Sci. Rep. 6 (2016) 21914. W. Wang, et al., Loss of Apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic Apelin analogues, J. Am. Heart Assoc. 2 (4) (2013), e00249. S.M. McKinnie, et al., The converse:一切都无效化了 Apelin peptides, Chembiochem 17 (16) (2016) 1495–1498. A.F. Ceylan-ilk, et al., Apelin administration ameliorates high fat diet-induced cardiac hypertrophy and contractile dysfunction, J. Mol. Cell. Cardiol. 63 (2013) 41–13. A.H. Baker, D.R. Edwards, G. Murphy, Metalloproteinase inhibitors: biological actions and therapeutic opportunities, J. Cell Sci. 115 (Pt 19) (2002) 3719–3727. L. Moore, et al., Tissue inhibitor of metalloproteinases (TIMPs) in heart failure, Heart Fail. Rev. 17 (4–5) (2012) 693–706. V. Kandalam, et al., Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress, Circulation 124 (19) (2011) 2094–2105. R. Basu, et al., TIMPs is the primary TIM to regulate agonist-induced vascular remodelling and hypertension, Cardiovasc. Res. 98 (3) (2013) 360–371. D.T. Hsu, et al., Enalapril in infants with single ventricle: results of a multicenter randomized trial, Circulation 122 (4) (2010) 333–340. S. Shah, et al., Novel dominant-negative mutation in cardiac troponin I causes severe restrictive cardiomyopathy, Circ. Heart Fail. 10 (2) (2017), e003820. B. Misiek Nichols, et al., Advanced dilated cardiomyopathy in a patient with Hutterite limb-girdle muscular dystrophy: use of a left ventricular assist device, Circ. Heart Fail. 11 (4) (2018), e004966. H. Yogasundaram, et al., Glycogen storage disease because of a PRKAG2 mutation causing severe biventricular hypertrophy and high-grade atrio-ventricular block, Circ. Heart Fail. 9 (8) (2016), e003567. H. Yogasundaram, et al., Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiologi, diagnosis, and treatment, Can. J. Cardiol. 30 (12) (2014) 1706–1715. H. Yogasundaram, et al., Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiologi, diagnosis, and treatment, Can. J. Cardiol. 30 (12) (2014) 1706–1715. R.E. Shaddy, et al., Carvedilol for children and adolescents with heart failure: a randomized controlled trial, JAMA 298 (10) (2007) 1171–1179. H. Yogasundaram, et al., Glycogen storage disease because of a PRKAG2 mutation causing severe biventricular hypertrophy and high-grade atrio-ventricular block, Circ. Heart Fail. 9 (8) (2016), e003567. H. Yogasundaram, et al., Glycogen storage disease because of a PRKAG2 mutation causing severe biventricular hypertrophy and high-grade atrio-ventricular block, Circ. Heart Fail. 9 (8) (2016), e003567. H. Yogasundaram, et al., Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiologi, diagnosis, and treatment, Can. J. Cardiol. 30 (12) (2014) 1706–1715. H. Yogasundaram, et al., Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiologi, diagnosis, and treatment, Can. J. Cardiol. 30 (12) (2014) 1706–1715. H. Yogasundaram, et al., Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiologi, diagnosis, and treatment, Can. J. Cardiol. 30 (12) (2014) 1706–1715. A. Nijkamp, et al., Cardiac intervention improves heart disease and clinical outcomes in patients with muscular dystrophy in a multidisciplinary care setting, J. Am. Heart Assoc. 9 (2) (2020), e014004. A. Nijkamp, et al., Comparison of usefulness of cardiac resynchronization therapy in patients with type 1 myotonic dystrophy with versus without left bundle branch block, Am. J. Cardiol. 124 (11) (2019) 1770–1774. A. Nijkamp, et al., Ventricular tachycardia in patients with type 1 myotonic dystrophy: a case series, Eur. J. Heart Case Rep. 3 (2) (2019) (p. ytz095). G. Iacobellis, H.J. Williams, Echocardiographic epicaldial fat: a review of research and clinical applications, J. Am. Soc. Echocardiogr. 22 (12) (2009) 1311–1319 quiz 1471-9. A.H. Talman, et al., Epicaldipe adipose tissue: far more than a fat depot, Cardiovasc. Diagn. Ther. 4 (6) (2014) 416–429.
[170] G. Iacobellis, Epicardial and pericardial fat: close, but very different, Obesity 17 (4) (2009) 625 (author reply 626-7).
[171] R. Rafeh, et al., Targeting perivascular and epicardial adipose tissue inflammation: therapeutic opportunities for cardiovascular disease, Clin. Sci. (Lond.) 134 (7) (2020) 827-851.
[172] D. Corradi, et al., The ventricular epicardial fat is related to the myocardial mass in normal, ischemic and hypertrophic hearts, Cardiovasc. Pathol. 13 (6) (2004) 313-316.
[173] G. Iacobellis, A.C. Bianco, Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features, Trends Endocrinol. Metab. 22 (11) (2011) 450-457.
[174] V.B. Patel, et al., Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease, Heart Fail. Rev. 22 (6) (2017) 889-902.
[175] T. Mazurek, et al., Human epicardial adipose tissue is a source of inflammatory mediators, Circulation 108 (20) (2003) 2460-2466.
[176] Y. Yamaguchi, et al., Adipogenesis and epicardial adipose tissue: a novel fate of the epicardium induced by mesenchymal transformation and PPARgamma activation, Proc. Natl. Acad. Sci. U. S. A. 112 (7) (2015) 2070-2075.
[177] S.M. Al-Khatib, et al., 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society, J. Am. Coll. Cardiol. 72 (14) (2018) e91-e220.
[178] F.X. Witkowski, et al., Spatiotemporal evolution of ventricular fibrillation, Nature 392 (6671) (1998) 78-82.
[179] P. Zhabyeyev, et al., Inhibition of PI3Kinase-α is pro-arrhythmic and associated with enhanced late Na(+) current, contractility, and Ca(2+) release in murine hearts, J. Mol. Cell. Cardiol. 132 (2019) 98-109.
[180] A. Mihic, et al., Trafficking defect and proteasomal degradation contribute to the phenotype of a novel KCNH2 long QT syndrome mutation, PLoS One 6 (3) (2011) e18273.